<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156533</url>
  </required_header>
  <id_info>
    <org_study_id>PI Initiated</org_study_id>
    <secondary_id>11045</secondary_id>
    <nct_id>NCT00156533</nct_id>
  </id_info>
  <brief_title>Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing</brief_title>
  <official_title>Long Term Treatment With Zolpidem: The Relative Efficacy of Nightly (Quaque Hora Somni [QHS]) &amp; Intermittent Dosing and the Potential for Long Term Clinical Gains After Treatment Discontinuation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We want to assess whether &quot;how and when&quot; one takes sleep medication results in similar or
      different outcomes with respect to symptom relief. We also want to know whether taking
      medication for a period of time provides continued benefit once the medication is stopped.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, the aggressive treatment (Tx) of chronic insomnia has been evaluated in terms of
      whether maintenance therapy is possible. While what constitutes maintenance therapy is a
      matter of debate, there are two studies which show that benzodiazepine receptor agonists
      (BZRAs) 1) are effective when used intermittently for up to 3 months and 2) may be used on a
      nightly basis for up to 6 months with no loss of efficacy.

      The significance of the present research is two fold. First, it will allow us to compare the
      two primary strategies used for long term treat of insomnia (nightly dosing vs intermittent
      dosing). Second, it will allow an evaluation of the possibility that extended treatment,
      given careful withdrawal from medication, may yield long term clinical gains.

      Re: Objective 1: It is widely assumed that intermittent dosing confers increased efficacy.
      That is, less frequent medication use will extend the duration of time for which the
      medication is maximally potent. An empirical assessment of this proposition is required. If
      incorrect, physicians and patients should be encouraged to adopt a more aggressive approach
      to treatment. If correct, physicians and patients should be encouraged to adopt the
      intermittent dosing approach to treatment.

      Re: Objective 2: It is widely assumed that treatment with sedatives (sleep promoting
      medications) constitutes only palliative care. An empirical assessment of this proposition is
      required. If correct, physicians and patients should be encouraged to adopt a more aggressive
      approach to long term treatment. If incorrect, physicians and patients should be encouraged
      to adopt an approach to treatment that is not currently a standard of practice: extended
      treatment with a clear plan to taper medication that is designed to maintain the clinical
      gains that occurred with medication use.

      We propose to evaluate the above issues in a pilot study of 40 subjects with Primary Insomnia
      where subjects are randomized to one of 4 conditions:

        1. QHS dosing with placebo

        2. QHS dosing with 10mg of zolpidem

        3. Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed)

        4. Monitor only condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep Latency (SL)</measure>
    <time_frame>Baseline and Post-treatment (12wks)</time_frame>
    <description>Number of subjects with any reduction in SL (time to fall asleep in minutes)at post-tx compared to baseline where mean SL = mean of daily values for one week calculated from sleep diary values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wake After Sleep Onset (WASO)</measure>
    <time_frame>Baseline and Post-Treatment (12 weeks)</time_frame>
    <description>Number of subjects with any reduction in WASO at post-tx compared to baseline where mean WASO = mean of daily values for one week calculated from sleep diary values.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Insomnia</condition>
  <condition>Primary Insomnia</condition>
  <condition>Psychophysiologic Insomnia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>QHS dosing with placebo (i.e. nightly dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QHS Zolpidem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QHS dosing with 10mg of zolpidem (i.e. nightly dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittant Zolpidem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Monitor only condition (no placebo, no drug).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>10 mg of Zolpidem</description>
    <arm_group_label>QHS Zolpidem</arm_group_label>
    <arm_group_label>Intermittant Zolpidem</arm_group_label>
    <other_name>Ambien</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 25 - 55

          -  a stable sleep/wake schedule with a preferred sleep phase between 10:00 p.m. and 8:00
             a.m.

          -  Patients with Primary Insomnia will meet diagnostic criteria for Psychophysiologic
             Insomnia according to the International Classification of Sleep Disorders manual
             (ICSD).

          -  complaint of disturbed sleep must have the following characteristics: &gt;30 minutes to
             fall asleep, and/or &gt;30 minutes wake after sleep onset time, a total sleep time of no
             more than 6.5 hours (or a sleep efficiency of less than 85%), a problem frequency of
             &gt;4 nights/ week and a problem duration &gt;6 months.

        Exclusion Criteria:

          -  Unstable medical or psychiatric illness

          -  Use of medication that may cause insomnia or may be reduce the effectiveness of
             zolpidem (e.g. selective serotonin reuptake inhibitors(SSRI's), steroids,
             bronchodilators, calcium channel blockers, beta blockers, etc.)

          -  symptoms suggestive of sleep disorders other than insomnia

          -  polysomnographic data indicating sleep disorders other than insomnia

          -  Evidence of active illicit substance use or fitting criteria for alcohol abuse or
             dependence

          -  inadequate language comprehension

          -  pregnancy

          -  first-degree relatives with bipolar disorder or schizophrenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L Perlis, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Sleep Research Laboratory</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>October 10, 2011</results_first_submitted>
  <results_first_submitted_qc>April 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2013</results_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Wilfred Pigeon, PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>Sleep</keyword>
  <keyword>zolpidem</keyword>
  <keyword>Ambien</keyword>
  <keyword>Hypnotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from television and newspaper ads. After a telephone or web based screening, subjects brought into the lab to read the Informed Consent Form (ICF). After the ICF has been signed, an initial medical and psychiatric evaluation completed. If the subjects remain eligible they are required to keep two weeks of sleep diaries.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Once nightly dosing (quaque hora somni [QHS])with placebo</description>
        </group>
        <group group_id="P2">
          <title>QHS (Nightly) Zolpidem</title>
          <description>Once nightly (QHS) dosing with 10mg of zolpidem</description>
        </group>
        <group group_id="P3">
          <title>Intermittant Zolpidem</title>
          <description>Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed</description>
        </group>
        <group group_id="P4">
          <title>CTRL</title>
          <description>Monitor only condition.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawn - Medication Expiration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed Screening</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>QHS dosing with placebo</description>
        </group>
        <group group_id="B2">
          <title>QHS Zolpidem</title>
          <description>QHS dosing with 10mg of zolpidem</description>
        </group>
        <group group_id="B3">
          <title>Intermittant Zolpidem</title>
          <description>Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed</description>
        </group>
        <group group_id="B4">
          <title>CTRL</title>
          <description>Monitor only condition.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sleep Latency (SL)</title>
        <description>Number of subjects with any reduction in SL (time to fall asleep in minutes)at post-tx compared to baseline where mean SL = mean of daily values for one week calculated from sleep diary values.</description>
        <time_frame>Baseline and Post-treatment (12wks)</time_frame>
        <population>Completers Only</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>QHS (i.e., nightly) dosing with placebo</description>
          </group>
          <group group_id="O2">
            <title>QHS Zolpidem</title>
            <description>QHS (i.e., nightly) dosing with 10mg of zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Intermittant Zolpidem</title>
            <description>Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed)</description>
          </group>
          <group group_id="O4">
            <title>CTRL</title>
            <description>Monitor only condition (no placebo and no zolpidem).</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Latency (SL)</title>
          <description>Number of subjects with any reduction in SL (time to fall asleep in minutes)at post-tx compared to baseline where mean SL = mean of daily values for one week calculated from sleep diary values.</description>
          <population>Completers Only</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wake After Sleep Onset (WASO)</title>
        <description>Number of subjects with any reduction in WASO at post-tx compared to baseline where mean WASO = mean of daily values for one week calculated from sleep diary values.</description>
        <time_frame>Baseline and Post-Treatment (12 weeks)</time_frame>
        <population>Completers</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>QHS (i.e., nightly) dosing with placebo</description>
          </group>
          <group group_id="O2">
            <title>QHS Zolpidem</title>
            <description>QHS (i.e., nightly) dosing with 10mg of zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Intermittant Zolpidem</title>
            <description>Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed</description>
          </group>
          <group group_id="O4">
            <title>CTRL</title>
            <description>Monitor only condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Wake After Sleep Onset (WASO)</title>
          <description>Number of subjects with any reduction in WASO at post-tx compared to baseline where mean WASO = mean of daily values for one week calculated from sleep diary values.</description>
          <population>Completers</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>QHS dosing with placebo</description>
        </group>
        <group group_id="E2">
          <title>QHS Zolpidem</title>
          <description>QHS dosing with 10mg of zolpidem</description>
        </group>
        <group group_id="E3">
          <title>Intermittant Zolpidem</title>
          <description>Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed</description>
        </group>
        <group group_id="E4">
          <title>CTRL</title>
          <description>Monitor only condition.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>About 25% of the target sample was obtained. As a result our capacity to detect trends and to calculate effect sizes was greatly diminished. Accordingly, our observations must be very limited in scope.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Wilfred Pigeon</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585 275-3374</phone>
      <email>wilfred_pigeon@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

